RxDoctor Payments Data

Drew Messerschmidt, MD

Cardiovascular Disease · Sioux Falls, SDNPI 1467848655

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Heartflow, Inc. accounts for 91.0% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for cardiovascular disease clinicians in SD, where the typical reported total is $1,542.

$195in general payments, 2019–2025

Across 4 payments — averaging $48.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$177
  • E.r. Squibb & Sons, L.L.C.$17
$93,929in research payments, 2019–2025

Across 7 payments — averaging $13,418 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$94K

What the payments were for

  • Food & beverage$195100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Heartflow, Inc.3$177
E.r. Squibb & Sons, L.L.C.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$195 in reported general payments places this provider in the 15th percentile of 33 cardiovascular disease providers in South Dakota.

See all cardiovascular disease providers in South Dakota

Medicare billing

Part B allowed, 2024
$135,294
Medicare patients
1,317
Services billed
2,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban305$230,064
XareltoRivaroxaban115$99,423
JardianceEmpagliflozin46$34,969
Repatha SureclickEvolocumab39$19,981
Rosuvastatin Calcium332$3,240
Metoprolol Succinate279$3,159
Atorvastatin Calcium233$1,722
Ezetimibe112$1,709
Potassium Chloride77$1,096
Carvedilol258$1,091
Losartan Potassium144$951
Furosemide288$946
Nifedipine ErNifedipine61$793
ClopidogrelClopidogrel Bisulfate82$697
Torsemide29$589

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →